Novo Nordisk
NVO
$132.92
Share price
0.39%
Change (1 day)
56.91%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Total liabilities
Total liabilities on the balance sheet as of March 2024 : $28.94 B
According to Novo Nordisk's latest financial reports the company's total liabilities are $28.94 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $30.79 B | 35.54% |
| 2022-12-31 | $22.72 B | 20.58% |
| 2021-12-31 | $18.84 B | 39.7% |
| 2020-12-31 | $13.48 B | 32.26% |
| 2019-12-31 | $10.19 B | 12.95% |
| 2018-12-31 | $9.02 B | 6.6% |
| 2017-12-31 | $8.47 B | 14.45% |
| 2016-12-31 | $7.40 B | 12.65% |
| 2015-12-31 | $6.56 B | 9.4% |
| 2014-12-31 | $6.00 B | 16.81% |
| 2013-12-31 | $5.14 B | 15.8% |
| 2012-12-31 | $4.43 B | -6.48% |
| 2011-12-31 | $4.74 B | 8.85% |
| 2010-12-31 | $4.36 B | 19.1% |
| 2009-12-31 | $3.66 B | 10.36% |
| 2008-12-31 | $3.31 B | 8.87% |
| 2007-12-31 | $3.04 B | 17.98% |
| 2006-12-31 | $2.58 B | 14.05% |
| 2005-12-31 | $2.26 B | 13.01% |
| 2004-12-31 | $2.00 B | 28.87% |
| 2003-12-31 | $1.55 B | 25.94% |
| 2002-12-31 | $1.23 B | -2.17% |
| 2001-12-31 | $1.26 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $137.21 B | 374.07% | 🇺🇸 USA |
 Eli Lilly LLY | $51.04 B | 76.36% | 🇺🇸 USA |
 Sanofi SNY | $57.61 B | 99.05% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | $82.48 B | 184.98% | 🇺🇸 USA |